EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer

A. Dewdney, J. Capdevila, B. Glimelius, A. Cervantes, D.M. Tait, G. Brown, A. Wotherspoon, D.G. de Castro, Y.J. Chua, R. Wong, Y. Barbachano, J.R. Oates, I. Chau, D. Cunningham

Research output: Contribution to journalArticlepeer-review

Cite this